CorMedix Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.89
- Today's High:
- $4.025
- Open Price:
- $3.89
- 52W Low:
- $2.65
- 52W High:
- $8.03
- Prev. Close:
- $3.9
- Volume:
- 394385
Company Statistics
- Market Cap.:
- $232.33 million
- Book Value:
- 1.212
- Revenue TTM:
- $57772
- Operating Margin TTM:
- -59905.81%
- Gross Profit TTM:
- $61674
- Profit Margin:
- 0%
- Return on Assets TTM:
- -34.84%
- Return on Equity TTM:
- -58.41%
Company Profile
CorMedix Inc had its IPO on 2010-03-25 under the ticker symbol CRMD.
The company operates in the Healthcare sector and Biotechnology industry. CorMedix Inc has a staff strength of 40 employees.
Stock update
Shares of CorMedix Inc opened at $3.89 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.89 - $4.03, and closed at $3.99.
This is a +2.31% increase from the previous day's closing price.
A total volume of 394,385 shares were traded at the close of the day’s session.
In the last one week, shares of CorMedix Inc have slipped by -3.39%.
CorMedix Inc's Key Ratios
CorMedix Inc has a market cap of $232.33 million, indicating a price to book ratio of 2.7711 and a price to sales ratio of 1837.6884.
In the last 12-months CorMedix Inc’s revenue was $57772 with a gross profit of $61674 and an EBITDA of $-34527556. The EBITDA ratio measures CorMedix Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, CorMedix Inc’s operating margin was -59905.81% while its return on assets stood at -34.84% with a return of equity of -58.41%.
In Q1, CorMedix Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 47.3%.
CorMedix Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.85 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into CorMedix Inc’s profitability.
CorMedix Inc stock is trading at a EV to sales ratio of 1062.7267 and a EV to EBITDA ratio of -3.2885. Its price to sales ratio in the trailing 12-months stood at 1837.6884.
CorMedix Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $59.23 million
- Total Liabilities
- $4.67 million
- Operating Cash Flow
- $-14686805.00
- Capital Expenditure
- $14766
- Dividend Payout Ratio
- 0%
CorMedix Inc ended 2024 with $59.23 million in total assets and $0 in total liabilities. Its intangible assets were valued at $59.23 million while shareholder equity stood at $-285928012.00.
CorMedix Inc ended 2024 with $0 in deferred long-term liabilities, $4.67 million in other current liabilities, 44500.00 in common stock, $-285928012.00 in retained earnings and $0 in goodwill. Its cash balance stood at $25.50 million and cash and short-term investments were $55.83 million. The company’s total short-term debt was $138,623 while long-term debt stood at $0.
CorMedix Inc’s total current assets stands at $56.78 million while long-term investments were $0 and short-term investments were $30.33 million. Its net receivables were $0 compared to accounts payable of $1.45 million and inventory worth $0.
In 2024, CorMedix Inc's operating cash flow was $-14686805.00 while its capital expenditure stood at $14766.
Comparatively, CorMedix Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.99
- 52-Week High
- $8.03
- 52-Week Low
- $2.65
- Analyst Target Price
- $16.67
CorMedix Inc stock is currently trading at $3.99 per share. It touched a 52-week high of $8.03 and a 52-week low of $8.03. Analysts tracking the stock have a 12-month average target price of $16.67.
Its 50-day moving average was $4.04 and 200-day moving average was $4.34 The short ratio stood at 7.25 indicating a short percent outstanding of 0%.
Around 108.1% of the company’s stock are held by insiders while 2563.3% are held by institutions.
Frequently Asked Questions About CorMedix Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath and Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.